JPMorgan Chase & Co. reissued their buy rating on shares of Roche (VTX:ROG) in a report released on Thursday morning.

ROG has been the subject of a number of other research reports. Goldman Sachs Group set a CHF 325 price objective on Roche and gave the company a buy rating in a research note on Thursday, October 12th. Morgan Stanley set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Friday, November 17th. Deutsche Bank set a CHF 264 price objective on Roche and gave the company a neutral rating in a research note on Tuesday, December 12th. Liberum Capital set a CHF 279 price objective on Roche and gave the company a buy rating in a research note on Wednesday, November 22nd. Finally, Baader Bank set a CHF 231 price objective on Roche and gave the company a neutral rating in a research note on Thursday, October 19th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of CHF 263.42.

Shares of Roche (VTX ROG) traded up CHF 1.30 during trading on Thursday, reaching CHF 245.80. The company’s stock had a trading volume of 1,680,000 shares, compared to its average volume of 1,550,000. Roche has a 12-month low of CHF 226.10 and a 12-month high of CHF 273. The firm has a market capitalization of $212,060.00 and a PE ratio of 21.85.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/01/12/roche-rog-receives-buy-rating-from-jpmorgan-chase-co.html.

Roche Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.